Korro Bio: Development and Application of Graph Neural Networks to Design Guide Oligonucleotides that Promote RNA Editing
March 13, 2024 at 01:58 pm EDT
Share
U n l o c k i n g t h e O P E R A P l a t f o r m
Development and Application of Graph
Neural Networks to Design Guide
Oligonucleotides that Promote RNA Editing
Overview of Topics
Korro Bio Methodology
Machine Learning for Chemically Modified Oligonucleotide Design
Methods for Increasing Use-Cases for ML Oligonucleotide Design
New Chemical Modifications
New Targets
2
RNA Editing: Transiently Effecting anA-to-I Edit on RNA Using anOligonucleotide
1
2 Oligo-RNA duplex recruits adenosine deaminase acting on RNA (ADAR)
3 ADAR catalyzes deamination: 'A' to 'I' edit
DNA with disease-
ADAR
ADAR
Adenosine
Inosine
causing mutation
Target
RNA
4 mRNA translated to protein with 'I' read as 'G'
5 Resultant therapeutic protein
3
OPERA: Our Differentiated Approach for RNA Editing
Deep understanding of
Expertise in oligonucleotide
ADAR biology
chemistry
Fit-for-purpose delivery
Machine learning optimization
of oligonucleotides
1 IP estate count as of September 18, 2023
4
Chemical Modifications are Employed to Drive Activity and Stability
Examples of chemical modifications in
approved products
Korro leverages established and novel chemical modifications to improve pharmacology of ADAR guide oligonucleotides
5
Chemical Modification Pattern Significantly Impacts Editing of Target mRNA
Editing
Sequence
6
Overview of Topics
Korro Bio Methodology
Machine Learning for Chemically Modified Oligonucleotide Design
Methods for Increasing Use-Cases for ML Oligonucleotide Design
New Chemical Modifications
New Targets
7
Sequence-Level Featurization
Structural Features
Entity Embeddings
8
Sequence-Level Featurization
Tree-based Models
Entity Embeddings
Convolutional Neural Network
9
Our Model Learns the Effect of Chemical Modification Patterns on In Vitro Editing
r = 0.80
• Model tested on 20% of in vitro data for a single target
• Understanding of relationship between sequence, chemical modifications and in vitro editing
• Predictions within 7% of in vitro editing
10
Attachments
Original Link
Original Document
Permalink
Disclaimer
Korro Bio Inc. published this content on
13 March 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
13 March 2024 17:57:07 UTC.
Korro Bio, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the bodyâs natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. OPERA co-opts the cellâs natural process with its synthetic oligo and catalyzes a single base change to modify protein sequence and function without the need to permanently modify oneâs genome. The Company's focus areas include the liver and central nervous system (CNS).